Open AccessRecent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease
Author(s) -
Xiaoying Si,
Didier Merlin,
Bo Xiao
Publication year - 2016
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v22.i34.7718
Subject(s) - medicine , inflammatory bowel disease , drug , adverse effect , disease , gastrointestinal tract , pharmacology , cell , drug delivery , immunology , bioinformatics , biology , chemistry , organic chemistry , genetics
Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment.